Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

American Journal of Hematology

Volumn 90, Issue 8, 2015, Pages 732-736

  Dinardo, Courtney D ^a   Ravandi, Farhad ^a   Agresta, Sam ^b   Konopleva, Marina ^a   Takahashi, Koichi ^a   Kadia, Tapan ^a   Routbort, Mark ^a   Patel, Keyur P ^a   Mark Brandt, ^a   Pierce, Sherry ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AGIOS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; NUCLEAR PROTEIN; NUCLEOPHOSMIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; ADOLESCENT; COHORT ANALYSIS; GENE EXPRESSION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SALVAGE THERAPY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 84937398063     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24072     Document Type: Article

References (31)

1. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-234. PubMed PMID: 20171147. Pubmed Central PMCID: 2849316. Epub 2010/02/23. eng.
2. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010;102:932-941. PubMed PMID: 20513808. Pubmed Central PMCID: 2897878. Epub 2010/06/02. eng.
3. Wise DR, Ward PS, Shay JE, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA 2011;108:19611-19616. PubMed PMID: 22106302. Pubmed Central PMCID: 3241793. Epub 2011/11/23. eng.
4. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483:474-478. PubMed PMID: 22343901. Epub 2012/02/22. eng.
5. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553-567. PubMed PMID: 21130701. Epub 2010/12/07. eng.
6. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-2074. PubMed PMID: 23634996. Pubmed Central PMCID: 3767041.
7. Kernytsky A, Wang F, Hansen E, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood 2015;125:296-303. PubMed PMID: 25398940.
8. Im AP, Sehgal AR, Carroll MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: Associations with prognosis and potential treatment strategies. Leukemia 2014;28:1774-1783. PubMed PMID: 24699305. Pubmed Central PMCID: 4234093.
9. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28:3636-3643. PubMed PMID: 20567020. Epub 2010/06/23. eng.
10. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348-2355. PubMed PMID: 20368543. Pubmed Central PMCID: 2881719. Epub 2010/04/07. eng.
11. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079-1089. PubMed PMID: 22417203. Epub 2012/03/16. eng.
12. Rampal R, Alkalin A, Madzo J, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep 2014;9:1841-1855. PubMed PMID: 25482556. Pubmed Central PMCID: 4267494.
13. Zhou KG, Jiang LJ, Shang Z, et al. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: A meta-analysis. Leuk Lymphoma, 2012;53:2423-2429. PubMed PMID: 22616558.
14. DiNardo CD, Propert KJ, Loren AW, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 2013;121:4917-4924. PubMed PMID: 23641016. Pubmed Central PMCID: 3682342.
15. Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011;118:409-412. PubMed PMID: 21596855.
16. Rockova V, Abbas S, Wouters BJ, et al. Risk stratification of intermediate-risk acute myeloid leukemia: Integrative analysis of a multitude of gene mutation and gene expression markers. Blood 2011;118:1069-1076. Jul 28;PubMed PMID: 21596848.
17. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-1066. PubMed PMID: 19657110. Pubmed Central PMCID: 3201812. Epub 2009/08/07. eng.
18. Ravandi F, Patel K, Luthra R, et al. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 2012;118:2665-2673. PubMed PMID: 22020636. Epub 2011/10/25. eng.
19. Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value. Blood 2010;116:2122-2126. PubMed PMID: 20538800. Epub 2010/06/12. eng.
20. Nomdedeu J, Hoyos M, Carricondo M, et al. Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group. Leuk Res 2012;36:990-997. PubMed PMID: 22520341. Epub 2012/04/24. eng.
21. Chotirat S, Thongnoppakhun W, Promsuwicha O, et al. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol 2012;5:5. PubMed PMID:. Pubmed Central PMCID: 3320529. Epub 2012/03/09. eng.
22. Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011;118:5593-5603. PubMed PMID: 21881046.
23. Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24:1094-1096. PubMed PMID: 20376084.
24. Wagner K, Damm F, Gohring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28:2356-2364. PubMed PMID: 20368538. Epub 2010/04/07. eng.
25. Thol F, Damm F, Wagner K, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010;116:614-616. PubMed PMID: 20421455.
26. Patel KP, Ravandi F, Ma D, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: Frequency and clinicopathologic features. Am J Clin Pathol 2011;135:35-45. PubMed PMID: 21173122. Epub 2010/12/22. eng.
27. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083. PubMed PMID: 11110676. Epub 2000/12/09. eng.
28. Stein EM, Altman JK, Collins R, et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. Blood 2014;124:115. (Oral ASH Abstract).
29. Yaqub F. Inhibition of mutant IDH1 in acute myeloid leukaemia. Lancet Oncol 2015;16:e9. PubMed PMID: 25638561.
30. Giles F, O'Brien S, Cortes J, et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer 2005;104:547-554. PubMed PMID: 15973664.
31. Pemmaraju N, Kantarjian H, Garcia-Manero G, et al. Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. Am J Hematol 2015;90:27-30. PubMed PMID: 25251041. Pubmed Central PMCID: 4276516.